Development and usability of a new subcutaneous auto-injector device to administer hydroxyprogesterone caproate to reduce the risk of recurrent preterm birth

References

• MartinJAHamiltonBEOstermanMJDriscollAKMathewsTJBirths: final data for 2015Natl Vital Stat Rep20176611
   PubMedGoogle Scholar
• March of Dimes2017 Premature Birth Report Card Available from: https://www.marchofdimes.org/materials/PrematureBirthReportCard-United-States-2017.pdfAccessed November 14, 2017
   Google Scholar
• OstermanMJKochanekKDMacDormanMFStrobinoDMGuyerBAnnual summary of vital statistics: 2012–2013Pediatrics201513561115112525941306
   PubMed Web of Science ®Google Scholar
• VohrBLong-term outcomes of moderately preterm, late preterm, and early term infantsClin Perinatol201340473975124182959
   PubMed Web of Science ®Google Scholar
• ManuckTAShengXYoderBAVarnerMWCorrelation between initial neonatal and early childhood outcomes following preterm birthAm J Obstet Gynecol20142105426.e1426.e924793722
   PubMed Web of Science ®Google Scholar
• NatarajanGShankaranSShort- and long-term outcomes of moderate and late preterm infantsAm J Perinatol201633330531726788789
   PubMed Web of Science ®Google Scholar
• IamsJDGoldenbergRLMercerBMThe Preterm Prediction Study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units NetworkAm J Obstet Gynecol19981785103510409609580
   PubMed Web of Science ®Google Scholar
• MercerBMGoldenbergRLMoawadAHThe Preterm Prediction Study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome National Institute of Child Health and Human Development Maternal-Fetal Medicine Units NetworkAm J Obstet Gynecol19991815 Pt 11216122110561648
   PubMed Web of Science ®Google Scholar
• KeirseMJProgestogen administration in pregnancy may prevent preterm deliveryBr J Obstet Gynaecol19909721491542138496
   PubMedGoogle Scholar
• MeisPJKlebanoffMThomEPrevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproateN Engl J Med2003348242379238512802023
   PubMed Web of Science ®Google Scholar
• FeghaliMVenkataramananRCaritisSPrevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerationsSemin Perinatol201438851652225256193
   PubMed Web of Science ®Google Scholar
• Committee on Practice Bulletins-Obstetrics, The American College of Obstetricians GynecologistsPractice bulletin no. 130: prediction and prevention of preterm birthObstet Gynecol2012120496497322996126
   PubMedGoogle Scholar
• The American College of Nurse-MidwivesPosition statement: prevention of preterm labor and preterm birth2012 Available from: http://midwife.org/ACNM/files/ACNMLibraryData/UPLOADFILE-NAME/000000000274/Prevention%20of%20Preterm%20Labor%20and%20Preterm%20Birth%20June%202012.pdfAccessed April 22, 2017
   Google Scholar
• Society for Maternal-Fetal Medicine (SMFM) Publications CommitteeThe choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birthAm J Obstet Gynecol20172163B11B1328126367
   PubMed Web of Science ®Google Scholar
• Makena® (hydroxyprogesterone caproate) injection [prescribing information]Waltham, MAAMAG Pharmaceuticals, Inc2016
   Google Scholar
• PanlilioALOrelienJGSrivastavaPUEstimate of the annual number of percutaneous injuries among hospital-based healthcare workers in the United States, 1997–1998Infect Control Hosp Epidemiol200425755656215301027
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health, Centers for Disease Control and Prevention, National Institute for Occupational Safety and HealthPreventing needlestick injuries in health care settingsDHHS (NIOSH) Publication No. 2000-108111999 Available from: https://www.cdc.gov/niosh/docs/2000-108/pdfs/2000-108.pdfAccessed April 4, 2017
   Google Scholar
• JinJFZhuLLChenMThe optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injectionPatient Prefer Adherence2015992394226170642
   PubMed Web of Science ®Google Scholar
• SchiffMJaffeJFreundlichBMadsenPNew autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritisExpert Rev Med Devices201411544745524934630
   PubMed Web of Science ®Google Scholar
• FreundlichBKivitzAJaffeJSNearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitationsJ Clin Rheumatol201420525626025036562
   PubMed Web of Science ®Google Scholar
• Callis DuffinKBukhaloMBobonichMAUsability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experienceMed Devices (Auckl)2016936136927785115
   PubMedGoogle Scholar
• KropJKramerWGComparative bioavailability of hydroxyprogesterone caproate administered via intramuscular injection or subcutaneous autoinjector in healthy postmenopausal women: a randomized, parallel group, open-label studyClin Ther20173911223452354
   Web of Science ®Google Scholar
• US Food and Drug AdministrationGuidance for industry and Food and Drug Administration staff. Applying Human factors and usability engineering to medical devices Issued February 3, 2016. Available from: https://www.fda.gov/downloads/MedicalDevices/&/UCM259760.pdfAccessed April 23, 2017
   Google Scholar
• Association for the Advancement of Medical InstrumentationHuman factors engineering – design of medical devices. ANSI/AAMI HE75:2009/(R)20132010 Available from: http://my.aami.org/aamire-sources/previewfiles/HE75_1311_preview.pdfAccessed April 23, 2017
   Google Scholar
• International Organization for StandardizationMedical devices – part 1: application of usability engineering to medical devicesIEC 62366-1:2015Geneva: Switzerland2015
   Google Scholar
• WiklundMKendlerJStrochlicAYUsability testing of medical devicesBoca Raton, FLCRC Press, Taylor & Francis Group2011
   Google Scholar
• Brand-SchieberEMunjalSKumarRAndreADValladaoWRamirezMHuman factors validation study of 3 mg sumatriptan autoinjector, for migraine patientsMed Devices (Auckl)2016913113727313479
   PubMedGoogle Scholar
• RaffaRBTaylorRJrPergolizziJVJrNalamachuSEdwardsESEdwardsETApplication of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergenciesDrug Deliv Transl Res20177111027562292
   PubMed Web of Science ®Google Scholar
• CaritisSNSharmaSVenkataramananRPharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestationAm J Obstet Gynecol2011205140.e140.e821620357
   PubMed Web of Science ®Google Scholar